Coconut Oil in Treatment of Periodontitis

Efficacy of Locally Delivered Coconut Oil in Management of Stage II and III Grade B Periodontitis. A Randomized Controlled Clinical Trial

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06384638

Enrollment

Registered

2024-04-25

Start date

2022-02-15

Completion date

2024-02-09

Last updated

2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Keywords

Periodontitis, coconut oil, scaling and debridement

Brief summary

Virgin Coconut Oil (VCO) is a vegetable oil extracted from coconut fleshcontains unsaturated fatty acids in the form of oleic acid and linoleic acid and flavonoids which function as anti-inflammatory. Periodontitis is an inflammatory disease of the periodontal tissues with a high prevalence worldwide. The main etiology of plaque periodontitis is biofilm containing colonies of pathogenic microorganisms. The aim of the study is to evaluate and compare the effect of scaling and root debridement alone versus the use of topically applied coconut oil as adjunctive to scaling and root debridement in treatment of Stage II and III Grade B periodontitis.

Interventions

BIOLOGICALtopical application of coconut oil

topical application of coconut oil

OTHERscaling and debridement

scaling and debridement

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* patients age group \>35 years without ant systemic disease * Willing to take part in the study. Patients with more than 16 natural teeth and have test teeth with both mesial and distal neighboring teeth with periodontitis with clinical attachment loss \>3 mm and radiographic percentage of bone loss/age ranged between 0.25 to 1. * Patients with no history of allergies to coconut

Exclusion criteria

* smokers * pregnant * lactating women * Teeth with both endodontic-periodontal lesion.

Design outcomes

Primary

Measure	Time frame	Description
clinical parameters	3 months	clinical attachment loss

Secondary

Measure	Time frame	Description
Biological parameters	3 months	Tumor necrosis factor alpha (TNF- α) levels by using ELISA.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026